Expression of estrogen-related receptors in ovarian cancer and impact on survival.
Adenocarcinoma, Clear Cell
/ metabolism
Adenocarcinoma, Mucinous
/ metabolism
Biomarkers, Tumor
/ metabolism
Cystadenocarcinoma, Serous
/ metabolism
Endometrial Neoplasms
/ metabolism
Female
Follow-Up Studies
Humans
Ovarian Neoplasms
/ metabolism
Prognosis
Receptors, Estrogen
/ metabolism
Retrospective Studies
Survival Rate
ERRalpha Estrogen-Related Receptor
Estrogen-related receptors
Ovarian cancer
Overall survival
Progression-free survival
Tissue microarray
Journal
Journal of cancer research and clinical oncology
ISSN: 1432-1335
Titre abrégé: J Cancer Res Clin Oncol
Pays: Germany
ID NLM: 7902060
Informations de publication
Date de publication:
Sep 2021
Sep 2021
Historique:
received:
29
01
2021
accepted:
24
05
2021
pubmed:
6
6
2021
medline:
17
8
2021
entrez:
5
6
2021
Statut:
ppublish
Résumé
This study further approaches the role of estrogen-related receptors (ERRs) in ovarian cancer. Protein expression of ERRα, ERRβ and ERRγ in ovarian cancer was assessed and was correlated with ovarian cancer markers, steroid hormone receptors and cancer-associated genes. Additionally, we examined to what extent expression of ERRs affects survival of ovarian cancer patients. For this purpose, we established a tissue microarray from 208 ovarian cancer patients and performed immunohistochemical analyses of the mentioned proteins. ERRα and ERRγ protein could be detected at different levels in more than 90% of all ovarian cancer tissues, whereas expression of ERRβ was observed in 82.2% of the cases. ERRα was found to positively correlate with ovarian cancer marker CEA (p < 0.005) and ERRγ correlated with ERα (p < 0.001). Univariate survival analyses revealed that ERRα expression did not affect overall (OS) or progression-free survival (PFS) of ovarian cancer patients. In contrast, higher expression of ERRβ in serous ovarian cancers was found to lead to a significantly decreased OS (p < 0.05). The strongest impact on survival was exhibited by ERRγ. Lower expression of this receptor in women with serous ovarian cancers indicated significantly increased OS compared to those with higher levels of ERRγ (p < 0.05). Multivariate survival analyses revealed ERRγ as an independent prognostic marker regarding OS of patients with serous ovarian cancer. Our data demonstrating that ERR proteins are frequently expressed in ovarian cancer and high levels of ERRβ and ERRγ significantly decreased OS of serous ovarian cancer patients suggest that these proteins might be interesting therapy targets in this cancer entity.
Identifiants
pubmed: 34089362
doi: 10.1007/s00432-021-03673-9
pii: 10.1007/s00432-021-03673-9
pmc: PMC8310835
doi:
Substances chimiques
Biomarkers, Tumor
0
ESRRG protein, human
0
Receptors, Estrogen
0
estrogen receptor-related receptor beta
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2555-2567Subventions
Organisme : Uniwersytet Medyczny w Lublinie
ID : Dz. St. 327/18
Informations de copyright
© 2021. The Author(s).
Références
Methods Mol Biol. 2010;664:37-44
pubmed: 20690050
Mol Cancer. 2010 Mar 10;9:55
pubmed: 20219091
Int J Gynecol Cancer. 2012 Nov;22(9):1509-16
pubmed: 23051957
Cancer Res. 2007 May 15;67(10):4904-14
pubmed: 17510420
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
J Steroid Biochem Mol Biol. 2007 May;104(3-5):301-4
pubmed: 17509876
Cancer Res. 2010 Nov 15;70(22):9298-308
pubmed: 20870744
CA Cancer J Clin. 2018 Jul;68(4):284-296
pubmed: 29809280
Cancer Manag Res. 2018 Dec 12;10:6887-6895
pubmed: 30588094
BMC Cancer. 2017 May 8;17(1):319
pubmed: 28482871
Semin Oncol. 2002 Oct;29(5 Suppl 14):45-54
pubmed: 12422313
Anticancer Res. 2011 Feb;31(2):711-8
pubmed: 21378361
Mol Ther. 2014 Apr;22(4):743-51
pubmed: 24419103
J Biol Chem. 2015 May 8;290(19):12332-45
pubmed: 25805499
BMC Cancer. 2018 May 30;18(1):607
pubmed: 29843638
Cancer Res. 2002 Nov 15;62(22):6510-8
pubmed: 12438245
J Biol Chem. 2002 Jul 5;277(27):24826-34
pubmed: 11986328
Oncogene. 2008 May 22;27(23):3313-28
pubmed: 18071305
Endocr Relat Cancer. 2006 Dec;13 Suppl 1:S25-32
pubmed: 17259555
J Endocrinol. 2007 Jun;193(3):421-33
pubmed: 17535880
J Recept Signal Transduct Res. 2012 Apr;32(2):47-56
pubmed: 22268851
BMC Cancer. 2017 Aug 31;17(1):606
pubmed: 28859612
J Steroid Biochem Mol Biol. 2011 Jan;123(1-2):1-7
pubmed: 20883782
Int J Cancer. 2018 Oct 15;143(8):1963-1977
pubmed: 29756328
Oncotarget. 2017 Jan 10;8(2):3049-3058
pubmed: 27966445
PLoS One. 2012;7(6):e39102
pubmed: 22723937
Curr Top Med Chem. 2006;6(3):203-15
pubmed: 16515477
Endocr Relat Cancer. 2005 Dec;12(4):851-66
pubmed: 16322326
J Pathol. 2004 Mar;202(3):265-73
pubmed: 14991891
Cancer Manag Res. 2014 May 23;6:225-52
pubmed: 24904222
Cells. 2019 Oct 12;8(10):
pubmed: 31614769
Eur J Med Chem. 2017 Aug 18;136:457-467
pubmed: 28525844
Mol Endocrinol. 2006 May;20(5):1035-47
pubmed: 16439465
Genes Dev. 2020 Apr 1;34(7-8):544-559
pubmed: 32079653
Mol Oncol. 2014 Mar;8(2):337-50
pubmed: 24388361
J Mol Med (Berl). 2005 Jun;83(6):457-67
pubmed: 15770498
Int J Cancer. 2012 Jul 1;131(1):117-28
pubmed: 21823122
FASEB J. 2014 Jul;28(7):3124-33
pubmed: 24744145
Pathologe. 1987 May;8(3):138-40
pubmed: 3303008